Masterclass 6: From Venom to Value: Developing a Field-Deployable Antidote Through the FDA’s Rarely Used Animal Rule Pathway

From Venom to Value: Developing a Field-Deployable Antidote Through the FDA’s Rarely Used Animal Rule Pathway

Snakebite envenomation remains one of the most urgent yet under addressed emergencies in companion animals, where outcomes are often determined by how quickly treatment begins. This masterclass explores the development of a first in class, portable oral antidote designed for immediate, field based administration by pet owners, a broadly effective rescue therapy targeting toxin classes present in more than 95 percent of medically important snake species. Using Ophirex’s varespladib program as a case study, the session will examine the scientific rationale for mechanism based venom neutralization, cross species translational pharmacokinetic bridging, and the design of controlled animal models to establish efficacy when traditional placebo controlled trials in dogs and humans are unethical or infeasible.

It will further explore the unconventional application of FDA Animal Rule principles, including engagement with the Center for Veterinary Medicine, to advance approval under regulatory ambiguity. Participants will gain insight into aligning human and veterinary development pathways while creating parallel scientific and commercial value across markets, offering a strategic blueprint for innovators redefining how life saving veterinary therapeutics can be developed when conventional clinical pathways are not possible.

Jeremy Gowler (Ophirex)